Back Back
Cell No. : Cell Name
RCB1296 : HNT-34  update : 2022/04/04
CommentA human cell line derived from acute myeloid leukemia (AML). AML was originated from CMMoL. Possessing Philadelphia chromosome and t(3;3)(q21;q26). Expressing EVI1 and BCR/ABL. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
RIKEN BioResource Research Center, Cell Bank, 3-1-1 Koyadai,Tsukuba-shi, Ibaraki 305-0074 Japan
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Hamaguchi, Hiroyuki
Originator Hamaguchi, Hiroyuki
Year of deposit 1997
Animal human < Mammals
Genus Homo
Species sapiens
Gender Female
Age at sampling 45 years
Tissue blood
Disease name acute myelocytic leukemia
Classification cancer
Year of origin 1994
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_2071
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS (heat inactivated)
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 4-10 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) LT 400
Virus (HTLV-1) (-)
Isozyme LD, NP
Chromosome mode 45-47(50) : 45(3),46(46),47(1)
STR(human) OK
deposit info
lot info
Reference information Reference 1
User's Publication 2

To topTop
2171  Hamaguchi H, Suzukawa K, Nagata K, Yamamoto K, Yagasaki F, Morishita K  Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome.  Br J Haematol  1997  98:399-407  PubMed ID: 9266939   DOI: 10.1046/j.1365-2141.1997.2143029.x

To topTop
User's Publication
9218  Norio Yamakawa, Kazuko Kaneda, Yusuke Saito, Emi Ichihara, Kazuhiro Morishita  The Increased Expression of Integrin α6 (ITGA6) Enhances Drug Resistance in EVI1(high) Leukemia  PLoS One  2012  7(1):e30706  PubMed ID: 22295105   DOI: 10.1371/journal.pone.0030706
7886  Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K.  CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.  Leukemia  2011  25:921-31  PubMed ID: 21394097   DOI: 10.1038/leu.2011.36

Back Back Return Top Page